Suzetrigine: A novel nonopioid systemic analgesic

Suzetrigine: A novel nonopioid systemic analgesicO pioids have been the mainstay of postoperative analgesia for decades.However, their side effects and potential complications, such as respiratory depression, postoperative nausea, vomiting, and ileus, have fueled the search for alternative ways to control pain.Thus, the concept of multimodal analgesia was born-a technique using a combination of different analgesic modalities, including acetaminophen, nonsteroidal anti-infl ammatories, N-methyl-D-aspartate receptor antagonists, intravenous lidocaine infusion, local anesthetic infi ltration, regional anesthesia, and peripheral nerve blocks, that can result in maximal pain relief with the minimum necessary dose of opioids to lessen their side effects.This strategy has coincided with the adoption of enhanced recovery after surgery protocols that have helped promote multimodal analgesia to minimize opioid use while permitting a more expedient recovery. 1ecently, suzetrigine, a voltage-gated sodium channel 1.8 (Na V 1.8) blocker, was approved by the US Food and Drug Administration (FDA), leading to interest in possibly adding this nonopioid analgesic to the multimodal analgesic regimen.